Long-term safety of hepatic hydroxymethyl glutaryl coenzyme a reductase inhibitors: The role of metabolism - Monograph for physicians

Archives of Internal Medicine

Volumn 160, Issue 15, 2000, Pages 2273-2280

  Bottorff, Michael ^a,c   Hansten, Philip ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CYCLOSPORIN; DILTIAZEM; ERYTHROMYCIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

AREA UNDER THE CURVE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; HUMAN; MYALGIA; MYOSITIS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS;

EID: 0034726386     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.15.2273     Document Type: Review

References (49)

1. Lennernas H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin Pharmacokinet. 1997;32:403-425.
2. White CM, Chow MSS. A review of HMG-CoA reductase inhibitors. US Pharmacist. January 1998; HS19-HS30.
3. Mevacor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 1694-1698.
4. Zocor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 1776-1780.
5. Pravachol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 808-811.
6. Lescol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 1862-1865.
7. Lipitor. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 2186-2169.
8. Baycol. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 603-606.
9. Hamelin B, Turgeon J. Hydrophilicity/ lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol Sci.. 1998;19:25-37.
10. Seldane. In: Physicians' Desk Reference. 52nd ed. Montvale, NJ: Medical Economics Co Inc; 1998: 1238-1244.
11. Hansten PD. Understanding drug-drug interactions. Sci Med. January/February 1998:16-25.
12. Cupp MJ, Tracy TS. Cytochrome P450: new nomenclature and clinical implications. Am Fam Physician. 1998;57:107-116.
13. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics: the dynamics of drug absorption, distribution, and elimination. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics 9th ed. New York, NY: McGraw-Hill Co; 1996:12-17.
14. Horsmans Y. Major cytochrome P-450 families: implications in health and liver diseases. Acta Gastroenter Belg. 1997;60:2-10.
15. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
16. Levy RH, Bajpai M. Phenytoin: interactions with other drugs-mechanistic aspects. In: Levy RH, Mattson RH. Meldrum BS, eds. Antiepileptic Drugs. 4th ed. New York, NY: Raven Press; 1995:329-338.
17. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279:1200-1205.
18. Bates DW, Spell N, Cullen DJ, et al, for the Adverse Drug Events Prevention Study Group. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
19. Hansten PD, Horn JR. Drug Interactions Analysis and Management. Vancouver, Wash: Applied Therapeutics; 1998.
20. Rizack MA. The Medical Letter Handbook of Adverse Drug Interactions. New Rochelle, NY: The Medical Letter; 1997.
21. Desager JP, Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglytaryl-coenzyme A reductase inhibitors. Clin Pharmacokinet. 1996; 31:348-371.
22. Boberg M, Angerbauer R, Fey P, et al. Metabolism of cerivastatin by human liver microsomes in vitro. Characterization of primary metabolic pathways and of cytochrome P450 enzymes involved. Drug Metab Dispos. 1997;25:321-331.
23. Transon C, Leemann T, Vogl N, Gayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by ± fluvastatin. Clin Pharmacol Ther. 1995;58: 412-417.
24. Trilli LE, Kelley CL, Aspinall SL, Kroner BA. Potential interaction between warfarin and fluvastatin. Ann Pharmacother. 1996;30:1399-1402.
25. Everett DW, Chando TJ, Didonato GC, Singhvi SM, Pan HY, Weinstein SH, Biotransformation of pravastatin sodium in humans. Drug Metab Dispos. 1991;19:740-748.
26. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. Interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther. 1998;64:369-377.
27. Kantola T, Kivist KT, Neuvonen PJ. Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther. 1998;64:58-65.
28. Neuvonen PJ, Jalava KM. Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther. 1996;60:54-61.
29. Neuvonen PJ, Kantola T, Kivist KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 1998;63:332-341.
30. Spach DH, Bauwens JE, Clark CD, Burke WG. Rhabdomyolysis associated with lovastatin and erythromycin use. West J Med. 1991;154:213-215.
31. Rosenberg AD, Neuwirth MG, Kagen LJ, Singh K, Fischer HD, Bernstein RL. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Analg. 1995;81:1089-1091.
32. Veerkamp JH, Smit JW, Benders AA, Oosterhof A. Effects of HMG-CoA reductase inhibitors on growth and differentiation of cultured rat skeletal muscle cells. Biochim Biophys Acta. 1996;1315: 217-222.
33. Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. N Engl J Med. 1995;333:664-665.
34. Ayanian JZ, Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis. Ann Intern Med. 1988;115:682-683.
35. Ballantyne CM, Radovancevic B, Farmer JA, et al. Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. J Am Coll Cardiol. 1992;19:1315-1321.
36. Corpier CL, Jones PH, Suki WN, et al. Rhabdomyolysis and renal injury with lovastatin use. JAMA. 1988;260:239-241.
37. Ahmad S. Diltiazem myopathy. Am Heart J. 1993; 126:1494-1495.
38. Meier C, Stey C, Brack T, Maggiorini M, Risti B, Krahenbuhl S. Rhabdomyolysis in patients treated with simvastatin/cyclosporine: role of the hepatic cytochrome P450 enzyme. Schweiz Med Wochenschr. 1995;125:1342-1346.
39. Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with current use of simvastatin and nefazodone [letter]. JAMA. 1997; 277:296.
40. Segaert MF, De Soete C, Vandewiele I, Verbanck J. Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant. 1996;11:1846-1847.
41. US Food and Drug Administration. Posicor Labeling Changes. Washington, DC: US Food and Drug Administration; December 18, 1997. Talk Paper No. not available.
42. Yang B-B, Siedlik PH, Smithers JA, Sedman AJ, Stern RH. Atorvastatin pharmacokinetic interactions with other CYP3A4 substrates: erythromycin and ethinyl estradiol [abstract]. Pharm Res. 1996;13(suppl 9):S437.
43. Norman DJ, Illingwortri DR, Munson J, Hosenpud J. Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. N Engl J Med. 1988;318:46-47.
44. Horn M. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals. Arch Dermatol. 1996;132:1254.
45. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet. 1998;351:1929-1930.
46. Decoulx E, Millaire A, De Groote P, Mahieux G, Ducloux G. Rhabdomyolysis with pravastatin and type I macrocreatine kinase. Ann Cardiol Angiol. 1993;42:267-269.
47. Ragazzi MB, Iacona I, Campana C, et al. Altered disposition of pravaslatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc. 1993;25:2732-2734.
48. Perault MC, Ladouch-Bures L, Dejean C, Delaunay C, Pouget Abadie JF, Vandel B. Rhabdomyolysis during pravastatin treatment. Therapie. 1993;48:487.
49. Biesenbach G, Janko O, Stuby U, Zazgornik J. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency. Nephrol Dial Transplant. 1996;11:2059-2060.